1.1. Objective

1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions

1.3. Research Methodology
1.3.1. List of Primary & Secondary Sources
1.3.2. Market Size Estimation
1.3.2.1. Assumption for the Study
1.3.2.2. Data Triangulation

Executive Summary: Global Opioid Withdrawal Syndrome (OWS) Market

3.1. Industry Value Chain Analysis
3.1.1. Research and Formulation
3.1.2. Development and Packaging
3.1.3. Sales and Distribution
3.1.4. End Users

3.2. Industry Outlook
3.2.1. Epidemiology and Patient Population
3.2.1.1. Key Findings
3.2.1.2. Epidem and Market Methodology
3.2.1.3. 7MM Incident Patient Population of Opioid Withdrawal Syndrome (OWS)
3.2.1.4. Country Wise-Epidemiology of Opioid Withdrawal Syndrome (OWS)
3.2.1.5. United States Epidemiology
3.2.1.5.1. Assumptions and Rationale
3.2.1.5.2. Total Prevalent Cases of OWS in the United States
3.2.1.5.3. Total diagnosed OWS cases in the United States
3.2.1.5.4. Total treatable OWS cases in the United States
3.2.1.6. EU5 Epidemiology
3.2.1.6.1. Germany
3.2.1.6.1.1. Assumptions and Rationale
3.2.1.6.1.2. Total Prevalent Cases of OWS in the Germany
3.2.1.6.1.3. Total diagnosed OWS cases in the Germany
3.2.1.6.1.4. Total treatable OWS cases in the Germany
3.2.1.6.2. France
3.2.1.6.2.1. Assumptions and Rationale
3.2.1.6.2.2. Total Prevalent Cases of OWS in the France
3.2.1.6.2.3. Total diagnosed OWS cases in the France
3.2.1.6.2.4. Total treatable OWS cases in the France
3.2.1.6.3. Italy
3.2.1.6.3.1. Assumptions and Rationale
3.2.1.6.3.2. Total Prevalent Cases of OWS in the Italy
3.2.1.6.3.3. Total diagnosed OWS cases in the Italy
3.2.1.6.3.4. Total treatable OWS cases in Italy
3.2.1.6.4. Spain
3.2.1.6.4.1. Assumptions and Rationale
3.2.1.6.4.2. Total Prevalent cases of OWS in the Spain
3.2.1.6.4.3. Total diagnosed OWS cases in the Spain
3.2.1.6.4.4. Total treatable OWS cases in Spain
3.2.1.6.5. United Kingdom
3.2.1.6.5.1. Assumptions and Rationale
3.2.1.6.5.2. Total Prevalent cases of OWS in the UK
3.2.1.6.5.3. Total diagnosed OWS cases in the UK
3.2.1.6.5.4. Total treatable OWS cases in UK
3.2.1.7. Japan Epidemiology
3.2.1.7.1. Assumptions and Rationale
3.2.1.7.2. Total Prevalent cases of OWS in the Japan
3.2.1.7.3. Total diagnosed OWS cases in the Japan
3.2.1.7.4. Total treatable OWS cases in Japan
3.2.2. Treatment and Management of Opioid Withdrawal Syndrome (OWS) 
3.2.2.1. Scope of Treatment
3.2.2.2. Treatment Guidelines
3.2.3. American Academy of Pediatrics guidelines for Opioid Withdrawal Syndrome (OWS) 
3.2.4. Unmet Needs
3.2.5. Marketed Therapies 
3.2.5.1. US Worldmeds or USWM, LLC 
3.2.5.1.1. Product Description
3.2.5.1.2. Regulatory Milestones
3.2.5.1.3. Clinical Development
3.2.5.1.4. Ongoing Current Pipeline Activity
3.2.5.1.5. Safety and efficacy
3.2.5.1.6. Product Profile
3.2.6. Emerging Therapies 
3.2.6.1. Aphios Corporation
3.2.6.1.1. Product Description
3.2.6.1.2. Other Development Activities
3.2.6.1.3. Clinical Development
3.2.6.1.4. Clinical Trials Information
3.2.6.1.5. Safety and Efficacy
3.2.6.1.6. Product Profile
3.2.6.2. Chiesi Farmaceutici S.p.A.
3.2.6.2.1. Product Description
3.2.6.2.2. Other Development Activities
3.2.6.2.3. Clinical Development
3.2.6.2.4. Clinical Trials Information
3.2.6.2.5. Safety and Efficacy
3.2.6.2.6. Product Profile
3.2.6.3. Titan Pharmaceuticals, Inc.
3.2.6.3.1. Product Description
3.2.6.3.2. Other Development Activities
3.2.6.3.3. Clinical Development
3.2.6.3.4. Clinical Trials Information
3.2.6.3.5. Safety and Efficacy
3.2.6.3.6. Product Profile
3.2.6.4.  BioDelivery Sciences International, Inc.
3.2.6.4.1. Product Description
3.2.6.4.2. Other Development Activities
3.2.6.4.3. Clinical Development
3.2.6.4.4. Clinical Trials Information
3.2.6.4.5. Safety and Efficacy
3.2.6.4.6. Product Profile
3.2.6.5. Alkermes Plc.
3.2.6.5.1. Product Description
3.2.6.5.2. Other Development Activities
3.2.6.5.3. Clinical Development
3.2.6.5.4. Clinical Trials Information
3.2.6.5.5. Safety and Efficacy
3.2.6.5.6. Product Profile
3.2.6.6. Indivior PLC
3.2.6.6.1. Product Description
3.2.6.6.2. Other Development Activities
3.2.6.6.3. Clinical Development
3.2.6.6.4. Clinical Trials Information
3.2.6.6.5. Safety and Efficacy
3.2.6.6.6. Product Profile

3.3. PESTLE Analysis

3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition

3.5. Market Dynamics and Trends
3.5.1. Key Trends
3.5.2. Growth Drivers
3.5.3. Restraints/ Challenges

3.6. Market Growth and Outlook
3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2018-2030
3.6.2. Pricing Analysis

3.7. Covid-19 Impact Assessment on Market Growth Trend
3.7.1. Growth Trend Shift Analysis
3.7.2. Industry Best Practices

3.8. Regulatory Landscape

4.1. Market Concentration Rate

4.2. Company Market Share Analysis (Value %), 2021

4.3. Competitor Mapping

5.1. Key Insights

5.2. Market Size and Forecast, 2018 – 2030 (US$ Mn)
5.2.1. Lucemyra (Lofexidine)
5.2.2. Methadone
5.2.3. Buprenorphine
5.2.4. Naltrexone
5.2.5. Others (Britlofex, Masimo Bridge, etc.)

6.1. Key Insights

6.2. Market Size and Forecast, 2018 – 2030 (US$ Mn)
6.2.1. U.S. 
6.2.2. Europe-5
6.2.2.1. The UK
6.2.2.2. Germany
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.3. Japan

7.1. Key Insights

7.2. Market Size and Forecast, 2018 – 2030 (US$ Mn)
7.2.1. By therapy

8.1. Key Insights

8.2. Market Size and Forecast, 2018 – 2030 (US$ Mn)
8.2.1. By therapy 

9.1. Key Insights

9.2. Market Size and Forecast, 2018 – 2030 (US$ Mn)
9.2.1. By therapy 

10.1. US Worldmeds LLC
10.2. Aphios Corporation
10.3. Chiesi Farmaceutici S.p.A.
10.4. Titan Pharmaceuticals, Inc.
10.5. BioDelivery Sciences International, Inc.
10.6. Alkermes and Indivior PLC